Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends

NEW YORK, Jan. 31, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends

http://www.reportlinker.com/p01090735/Biotech-Strategy-2012---Licensing-Collaboration-and-MA-Trends.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends

Summary

- Understand the various factors considered when structuring deal terms in strategic acquisitions, mergers, collaborations, and licensing.

- Identify potential takeover targets and partners, thereby maximizing your opportunities for consolidation, investment, and strategic partnerships.

- Organize your sales and marketing efforts by identifying the business regions and segments to maximize opportunities for consolidation, investment and strategic partnerships.

Table of Contents

1 Table of CContents 51.1 List of Tables 81.2 List of Figures 82 Introduction 92.1 Catalyst 92.1.1 Key Questions Answered 92.1.2 Key Benefits 102.2 Upcoming Related Reports 102.3 Recently published reports: 103 Historical Dealmaking Trends 113.1 Overview 113.2 Leading Deal Drivers 113.2.1 The Patent Cliff 113.2.2 Lack of R&D Innovation 143.2.3 Strategic Shift to Emerging Markets 153.3 Overall Deals in Review 153.3.1 Review by Deal Type 153.3.2 Review by Therapy Area 183.4 Biotech Deals in Review 194 Mergers and Acquisitions 204.1 Overview 204.2 Gilead Completes $11.1 Billion Acquisition of Pharmasset 224.2.1 Deal Description 224.2.2 Deal Analysis 234.3 GSK Acquires HGS in $3.6 Billion Deal 244.3.1 Deal Description 244.3.2 Deal Analysis 244.4 Valeant Pharmaceuticals Agrees $2.6 Billion Cash Deal for Medicis Acquisition 274.4.1 Deal Description 274.4.2 Deal Analysis 274.5 Amgen Acquires Micromet in $1.1 Billion Deal 294.5.1 Deal Description 294.5.2 Deal Analysis 294.6 Alexion Completes Acquisition of Enobia Pharma in $1.1 Billion Deal 314.6.1 Deal Description 314.6.2 Deal Analysis 314.7 Alkermes Acquires EDT from Elan in $1 Billion Deal 334.7.1 Deal Description 334.7.2 Deal Analysis 334.8 Celgene Acquires Avila Therapeutics in $947.0m Deal 354.8.1 Deal Description 354.8.2 Deal Analysis 354.9 Jazz Pharmaceuticals Completes $678.4m Acquisition of EUSA Pharma 374.9.1 Deal Description 374.9.2 Deal Analysis 374.10 Jazz Pharmaceuticals Completes $576.5m Merger with Azur Pharma 394.10.1 Deal Description 394.10.2 Deal Analysis 394.11 Biogen Idec Closes $562.5m Deal for the Acquisition of Stromedix 424.11.1 Deal Description 424.11.2 Deal Analysis 425 Licensing Deals 445.1 Overview 445.2 Acorda Signs Marketing License Agreement with Watson Pharma 455.2.1 Deal Description 455.2.2 Deal Analysis 455.3 Baxter Enters Potential $565.0m Deal with Onconova Therapeutics 465.3.1 Deal Description 465.3.2 Deal Analysis 475.4 Exelixis and Merck Involved in "PI3K-?" Licensing Deal 485.4.1 Deal Description 485.4.2 Deal Analysis 485.5 Momenta Enters into Follow-On Biologics Licensing Agreement with Baxter 505.5.1 Deal Description 505.5.2 Deal Analysis 505.6 Nektar and Roche Involved in Manufacturing License Deal 525.6.1 Deal Description 525.6.2 Deal Analysis 526 Collaborations/Partnerships 546.1 Overview 546.2 Ablynx Extends Nanobody Deal with Boehringer Ingelheim 556.2.1 Deal Description 556.2.2 Deal Analysis 566.3 Novartis Pens Partnership with the University of Pennsylvania 576.3.1 Deal Description 576.3.2 Deal Analysis 576.4 Ironwood Enters into Collaboration Agreement with Bionomics 596.4.1 Deal Description 596.4.2 Deal Analysis 596.5 J&J's Janssen Biotech Unit Inks Collaboration Deal with Genmab 606.5.1 Deal Description 606.5.2 Deal Analysis 616.6 Pfizer and Mylan Pharmaceuticals Enter into Generics Manufacturing Partnership 626.6.1 Deal Description 626.6.2 Deal Analysis 627 Future Outlook 657.1 Overview 657.2 Dealmaking Trends 657.2.1 Biotech companies, like Big Pharma, will pursue deals to increase their global presence 657.2.2 "Small Biotech" will continue to engage in M&A in attempts to make the leap to "Big Biotech" 667.2.3 Biotech deal-making will remain a source of IP for Big Pharma 668 Appendix 688.1 Bibliography 688.2 Abbreviations 708.3 Research Methodology 728.3.1 Coverage 728.3.2 Secondary Research 728.3.3 Expert Panel Validation 738.4 About the Authors 738.4.1 Analyst 738.4.2 Global Head of Healthcare Research and Consulting 738.5 About the Industry Dynamics Team 748.6 GlobalData 748.7 Contact Us 758.8 Disclosure Information 758.9 Disclaimer 75

List of Tables

Table 1: Recent and Upcoming US Patent Expirations 12Table 2: M&A Deals, 3Q11-3Q12 20Table 3: Gilead's Acquisition of Pharmasset 24Table 4: GSK's Acquisition of HGS 26Table 5: Valeant Pharmaceutical's Acquisition of Medicis 29Table 6: Amgen's Acquisition of Micromet 30Table 7: Alexion's Acquisition of Enobia Pharma 32Table 8: Alkermes' Acquisition of EDT from Elan 34Table 9: Celgene's Acquisition of Avila Therapeutics 36Table 10: Jazz Pharmaceuticals' Acquisition of EUSA Pharma 38Table 11: Jazz Pharmaceuticals' Merger with Azur Pharma 42Table 12: Biogen's Acquisition of Stromedix 43Table 13: Acorda's Licensing Agreement with Watson Pharma 46Table 14: Acorda's Licensing Agreement with Watson Pharma 48Table 15: Exelixis' Licensing Agreement with Merck 50Table 16: Momenta's Licensing Agreement with Baxter 51Table 17: Nektar's Licensing Agreement with Roche 53Table 18: Ablynx's Collaboration with BI 57Table 19: Novartis' Collaboration with the University of Pennsylvania 58Table 20: Ironwood's Collaboration with Bionomics 60Table 21: Janssen's Collaboration with Genmab 62Table 22: Pfizer's Collaboration with the Mylan Pharmaceuticals 64

List of Figures

Figure 1: FDA Approvals of NDAs and BLAs, FY2005-FY2011 14Figure 2: Deal Analysis - Total Number of Deals and Deal Values ($m), 3Q07-2Q12 16Figure 3: Deal Analysis - Deals Distribution, 3Q07-2Q12 17Figure 4: Top 10 Therapeutic Areas by number and Value of Deals, 3Q11-2Q12 18Figure 5: Biotech Deals Breakdown by Type, Q3 2011-Q3 2012 19Figure 6: M&A Spending, Q3 2011-Q3 2012 ($m) 22Figure 7: Xyrem Sales as Percentage of Jazz Pharmaceuticals' Annual Revenues, 2005-2011 ($m) 40Figure 8: Licensing Deals1, Q3 2011-Q3 2012 44Figure 9: Breakdown of Collaboration deals, Q3 2011-Q3 2012 ($m) 55Figure 10: Pfizer:Emerging Markets Revenues as a Percentage of Annual Revenues, 2006-2011 63

To order this report:Pharmaceutical Industry: Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker